Healthcare · Pharmaceuticals & Biotechnology
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).
Ranks #131 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 7 Apr 2021 | Ipca Laboratories Limitedip | Promoter | Buy | 0 | ₹0 |
| 14 Sep 2020 | Ipca Laboratories Limited | Promoter | Buy | 0 | ₹0 |
| 6 Feb 2020 | Ipca Laboratories Limited | Promoter | Buy | 0 | ₹0 |
| 2 Apr 2019 | Ajay Ravi | Promoter group | Buy | 0 | ₹0 |
| 1 Apr 2019 | Ipca Laboratories Limited | Promoter | Buy | 0 | ₹0 |
| 1 Apr 2019 | Avinash Ravi | Promoter | Buy | 0 | ₹0 |
| 1 Apr 2019 | Hemalata Ravi | Promoter | Buy | 0 | ₹0 |
| 4 Oct 2017 | Avinash Ravi | Immediate relative | Buy | 0 | ₹0 |
| 4 Oct 2017 | R T Ravi | Immediate relative | Sell | 0 | ₹0 |
| 25 Jul 2016 | Hemalata Ravi | Promoter | Buy | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 1 Oct 2026 | VAIBHAV UPADHYAY | Bulk | Buy | 742 | 66.7800 | NSE |
| 1 Oct 2026 | VAIBHAV UPADHYAY | Bulk | Sell | 120,268 | 66.6900 | NSE |
| 1 Oct 2026 | VAIBHAV UPADHYAY | Bulk | Sell | 120,268 | 66.6900 | NSE |
| 1 Oct 2026 | VAIBHAV UPADHYAY | Bulk | Buy | 742 | 66.7800 | NSE |
| 26 Nov 2024 | GUTTIKONDA RAJASEKHAR | Bulk | Buy | 143,843 | 115.8500 | NSE |
| 19 Jul 2024 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Sell | 371,224 | 115.1600 | NSE |
| 19 Jul 2024 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Buy | 371,224 | 114.9600 | NSE |
| 19 Jul 2024 | N.G.C.S. (P) LTD. | Bulk | Sell | 117,638 | 115.5200 | NSE |
| 19 Jul 2024 | N.G.C.S. (P) LTD. | Bulk | Buy | 117,638 | 115.3900 | NSE |
| 13 Aug 2021 | BRESCON VENTURES PRIVATE LIMITED | Bulk | Sell | 225,000 | 149.0700 | NSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 14 Sep 2005 | Agm/Dividend-30% Purpose Revised | — | — |
| 21 Sep 2004 | Dividend-80% | — | — |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| — | NAME_CHANGE | Name changed from Krebs Biochemicals Ltd. to Krebs Biochemicals & Industries Ltd. |
| 20 Sep 2023 | OTHER | Annual General Meeting |
| 15 Sep 2021 | OTHER | Annual General Meeting |
| 16 Sep 2020 | OTHER | Annual General Meeting |
| 13 Sep 2019 | OTHER | Annual General Meeting |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 6 Aug 2026 | Financial Results/Other business matters | Yes |
| 21 May 2026 | Financial Results/Other business matters | Yes |
| 9 Feb 2026 | Financial Results/Other business matters | Yes |
| 4 Nov 2025 | Financial Results/Other business matters | Yes |
| 7 Aug 2025 | Financial Results/Other business matters | Yes |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 5 Oct 2026 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | Krebs Biochemicals and Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
| 5 Oct 2026 | Company Update | Krebs Biochemicals & Industries Ltd-$ - 524518 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 |
| 29 Sep 2026 | AGM/EGM | Krebs Biochemicals & Industries Ltd-$ - 524518 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report |
| 29 Sep 2026 | Shareholders meeting | Krebs Biochemicals and Industries Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 29, 2026. Further, the company has informed the Exchange regarding voting results. |
| 29 Sep 2026 | Shareholders meeting | Krebs Biochemicals and Industries Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 29, 2026 |
| 29 Sep 2026 | AGM/EGM | Krebs Biochemicals & Industries Ltd-$ - 524518 - Shareholder Meeting / Postal Ballot-Outcome of AGM |
| 21 Sep 2026 | Trading Window | Krebs Biochemicals and Industries Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 21 Sep 2026 | Insider Trading / SAST | Krebs Biochemicals & Industries Ltd-$ - 524518 - Closure of Trading Window |
| 7 Sep 2026 | Company Update | Krebs Biochemicals & Industries Ltd-$ - 524518 - Announcement under Regulation 30 (LODR)-Newspaper Publication |
| 7 Sep 2026 | Updates | Krebs Biochemicals and Industries Limited has informed the Exchange regarding 'Machine Readable financial results for the quarter ended 30.06.2026.'. |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
